Pfizer director Ronald E. Blaylock acquires $499,072 in stock
Ronald E. Blaylock, a director at Pfizer Inc. (NYSE:PFE), purchased 19,457 shares of the company's common stock. The ...
FiercePharma16h
With new FDA approval, GSK joins Pfizer in the 5-in-1 meningococcal vaccine ring
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
Hosted on MSN18h
Pfizer’s Talzenna gains 14-months OS lead over mCRPC SoC
Results from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.
Moderna, Inc.: Working Hard But Competition Is Working Harder
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade)
Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.
Texas AG launches probe into controversial Chinese AI app DeepSeek: ‘Stealing the data of our citizens’
Texas Attorney General Ken Paxton has launched an investigation into DeepSeek, the upstart Chinese artificial intelligence ...
Starboard Value buys Pfizer, exits Humana in Q4
Jeffrey Smith’s Starboard Value disclosed in an SEC filing its holdings as of December 31, 2024. The fund’s new buys during the fourth quarter ...
Indiatimes20h
Pfizer Share Price
Pfizer Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Scrap for the year ending 31-Mar-2024.For the quarter ended 31-12-2024, the company has reported a Standalone Total ...